MARKET COMPOSITE
CSTL - Castle Biosciences Inc8:00:00 PM 4/15/2024
Price
$19.23
-0.83 (-4.14%)
Castle Biosciences, Inc., a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; and two late-stage proprietary products in development, which address cutaneous squamous cell carcinoma and suspicious pigmented lesions, which are indications with high clinical need in dermatological cancer. It offers test services through physicians, physician assistants, and nurse practitioners. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Financials
Quarterly financials
(USD)Dec 2023Q/Q
Revenue66.1MM+8%
Gross Profit53.7MM-
Cost Of Revenue12.4MM+10%
Operating Income-5.7MM-41%
Operating Expenses59.4MM-
Net Income-2.6MM-63%
R&D13MM+1%
G&A44.1MM-1%
Amortization2.3MM-0%
Interest Expense2K-
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Stock news